microdose glp-1 menopause Microdosing GLP‑1 in & Perimenopause GLP-1 Microdosing: A Slower, Smarter

A 2-way ANOVA was used to compare differences between GLP-1(2836) and the scrambled control across multiple doses or different mouse strains

Synthetic GLP-1 and GIP agonists bind to their respective receptors and elicit the same response as the endogenous hormones would

Key Takeaways: GLP-1 vs GIP Both are incretin hormones released by your intestines after eating GLP-1 primarily affects appetite, gastric emptying, and insulin secretion GIP influences insulin secretion, glucagon regulation, and fat metabolism Single GLP-1 agonists (semaglutide) produce 14.9% average weight loss Dual GLP-1/GIP agonists (tirzepatide) produce 22.5% average weight loss The dual action appears to create additive rather than merely overlapping effects Both receptor types play important roles in metabolic regulation Understanding the difference helps explain why tirzepatide shows superior results What Are Incretin Hormones

Kawai K, Ol IE, Perrelet A, U RH

Finan et al

GLP-1 stands for glucagon-like peptide-1, which is a hormone made in your small intestines